Survey finds smaller enterprises will drive life sciences in Scotland
Researchers have revealed that small- and medium-sized companies will by key in the growth of the life sciences sector in Scotland.
List view / Grid view
Researchers have revealed that small- and medium-sized companies will by key in the growth of the life sciences sector in Scotland.
A national vaccine tracking system in China will aim to be completed before 31 March 2020, a report has said.
ViiV Healthcare has filed submissions to the FDA and EMA for the first dispersible formulation of dolutegravir (DTG) for children living with HIV.
A new report from the FDA has shown that greater competition among generic drug makers is associated with lower generic drug prices.
The EMA’s CHMP has adopted a positive opinion for five medicines and recommended extending the indications for eight more.
The FDA has granted accelerated approval to Vyondys 53 for the treatment of patients with Duchenne muscular dystrophy containing a mutation of the dystrophin gene that is amenable to exon 53 skipping.
Marketing authorisation has been granted by the EC for Evenity® (romosozumab) to treat osteoporosis in postmenopausal women.
A new study could aid pharmaceutical companies in their drug development efforts after if found that a drug candidate is more likely to be approved for use if it targets a gene known to be linked to the disease.
Sanofi has announced it is to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion.
The House of Representatives has voted to approve Speaker Pelosi’s drug pricing bill in a Democrat-led chamber, say reports.
In a new study, COMP360 (psilocybin) was well tolerated in healthy volunteers which support further investigation of a simultaneous 1:1 therapeutic administration design.
A new report has been published which draws on expertise from within and beyond the pharmaceutical industry to make recommendations for pharma communicators.
Alkermes, Inc. have received the warning letter after a promotional material review found it failed to adequately represent the risks of using the drug Vivitrol for patients with opioid use disorder.
The newly signed deal between the US, Mexico and Canada will hold down the price of biologic drugs in the continent, according to a report.
The European Commission has approved the label extension for KALYDECO® (ivacaftor) to include the treatment of infants with cystic fibrosis between six and 12 months old.